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Considerations in the Critically Ill ESRD Patient
Balazs Szamosfalvi and Jerry Yee
ESRD patients are admitted more frequently to intensive care units (ICUs) and have higher mortality risks than the general population, and the main causes of critical illness among ESRD patients are cardiovascular events, sepsis, and bleeding. Once in the
ICU, hemodynamic stabilization and fluid-electrolyte management pose major challenges in oligoanuric patients. Selection of
renal replacement therapy (RRT) modality is influenced by the outpatient modality and access, as well as severity of illness, renal provider experience, and ICU logistics. Currently, most patients receive intermittent hemodialysis or continuous RRT with
temporary vascular access catheters. Acute peritoneal dialysis (PD) is less frequently utilized, and utility of outpatient PD is reduced after an ICU admission. Thus, preservation of current vascular accesses, while limiting venous system damage for future
access creations, is relevant. Also, dosing of small-solute clearance with urea kinetic modeling is difficult and may be supplanted by novel online clearance techniques. Medication dosing, coordinated with delivered RRT, is essential for septic patients treated with antibiotics. A comprehensive, standardized approach by a multidisciplinary team of providers, including
critical care specialists, nephrologists, and pharmacists, represents a nexus of care that can reduce readmission rates, morbidity, and mortality of vulnerable ESRD patients.
Q 2013 by the National Kidney Foundation, Inc. All rights reserved.
Key Words: Intermittent hemodialysis, Sustained low-efficiency dialysis, Online clearance monitor, Access recirculation
monitor, Optical oxygen saturation sensor

Introduction

Assessment of the ESRD Patient in the ICU

The incidence of developing dialysis-requiring ESRD is
approximately 400 patients per million population in the
United States.1 ESRD patients are several fold more frequently hospitalized and admitted to the intensive care
unit (ICU) than patients with normal kidney function.
The major causes of admission to the ICU are sepsis,2 particularly in patients on hemodialysis (HD) using a catheter
access, and cardiovascular (CVS) events (eg, acute myocardial infarction, cardiac arrest, congestive heart failure,
and cerebrovascular accident), with other common problems including HD access complications and gastrointestinal bleeding.3 The most important causes of mortality
are CVS events and sepsis.1,4 When compared with
patients with normal kidney function, ESRD patients in
the ICU have an increased risk of mortality, mostly
because of more severe comorbidity burden. ESRD
survivors of an ICU admission often remain chronically
ill after discharge and remain at a higher risk of
mortality, new CVS events, malnutrition, and hospital
re-admission for several months.3,5-7 This review will
discuss select aspects of caring for dialysis-dependent patients including the evolving concepts of measuring the
delivered dialysis dose, ultrafiltration (UF) monitoring,
and anticoagulation. Electrolyte and medication management issues were the subject of another recent review8 and
will be discussed only to a lesser extent here.

In addition to the acute illness precipitating the ICU
admission, ESRD patients may have a multitude of comorbidities, and it may be helpful if the nephrologist follows a comprehensive ‘‘checklist’’ on initial evaluation
(Table 1). The ICU admitting diagnosis, evaluation, and
treatment plan should be ascertained. The etiology and duration of ESRD; the outpatient dialysis modality and prescription; and any prior documentation of code status,
end-of-life wishes, and circumstances under which dialysis withdrawal is desired should be assessed from the history and records. If residual kidney function is present,
strategies should be used to preserve it, which is of particular importance in peritoneal dialysis (PD) patients. The
hepatitis B surface antigen status should be established,
and surface antigen-positive patients must be dialyzed in
isolation with dedicated equipment. The PD catheter and
exit site should be meticulously cared for by an experienced provider. The HD access should be examined daily
for patency and signs of infection and, in the case of an arteriovenous fistula (AVF) or graft (AVG), the extremity
should be protected from blood pressure cuffs, venipuncture, and the placement of an arterial catheter. This requirement should be emphasized to the ICU team and clearly
documented in the patient’s chart. The central veins draining the access arm should also be protected from venous
catheters. The use of central venous catheters (CVCs) in
the subclavian vein and of peripherally inserted CVCs
via veins that could be used in the future for AVF or
AVG creation should be avoided if possible. Ultrasound
guided placement of a triple lumen CVC in the left internal
jugular vein and preservation of the right internal jugular
vein for HD access might be a practical approach that
also avoids the use of femoral CVCs less preferred because
of the increased risk of infection and thrombosis and decreased mobility. Systemic blood samples often can be
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obtained during renal replacement therapy (RRT) or from
lower-cost alternative to extracorporeal blood purificathe arterial catheter, reducing the need for venipuncture
tion in developing countries.9 Usually, patients receive
CAPD with 4-6 exchanges a day with volume in the range
blood sampling. The extracellular and intravascular fluid
of 2-3 L adjusted to provide acceptable control of serum
volume status should be evaluated at least daily using
chemistry. However, continuing PD may be difficult or
a combination of physical examination, strict intake and
contraindicated in patients with severe Gram-negative,
output records, daily weight trends, and, when available,
polymicrobial, or fungal peritonitis; in patients who
hemodynamic monitoring data trends. UF goals should
require abdominal surgery; in patients with severe respithen be established in close communication with the ICU
ratory failure in which abdominal distension may further
team. The adequacy of small-solute clearance and electroimpair gas exchange; and in severely catabolic patients in
lyte and acid-base control with dialysis should be moniwhich CAPD may not provide sufficient acid-base and
tored closely. The medication administration record must
electrolyte control. As a result, survival of the PD techbe reviewed daily and when the RRT prescription is
nique during and after an ICU stay is markedly limited.10
changed to avoid the use of medications unsafe in ESRD
Therefore, the remainder of this section will cover in
(eg, succinylcholine, meperidine) and to ensure that drug
more detail the more prevalent HD techniques used to
dosing is adjusted for residual kidney function and delivsupport ESRD patients in the ICU.
ered RRT. Antibiotic dosing in particular has to be coordiMost ESRD patients are maintained on 3-times-a-week
nated with RRT and discussed frequently with the
intermittent hemodialysis (IHD) as outpatients and stay
pharmacist. Medications unique to this population (eg,
on this modality when admitted to the ICU. IHD machines
erythropoiesis stimulating agents, vitamin D compounds,
are designed to deliver 200and phosphate binders)
300 mL/minute diffusive
should also be reviewed and
CLINICAL SUMMARY
urea clearance (Kurea) and
used as warranted. Adequate
operate at a blood flow
nutrition should be ascer ESRD patients are more frequently admitted to the ICU and
(QB) of 300-500 mL/minute
tained daily, preferably by
have a higher mortality than patients with normal kidney
function.
and a dialysate flow (QD)
enteral feeding using a
of 400-1000 mL/minute
potassium- and phosphate The delivered dose of hemodialysis may be monitored
over a period of 3-5 hours.11
restricted formula or diet.
using online clearance to ensure correction of acid-base
and electrolyte changes and inform antibiotic dosing in
Critically ill ESRD patients
Citrate-antibiotic
dialysis
the ICU.
may not tolerate such incatheter locking solutions
tense therapy well, and the
are increasingly applied to
 Ultrafiltration goals should be defined together with the
ICU team to achieve protocol-driven optimization of hemouse of gentler, continuous
prevent catheter infection.
dynamics including central venous O2 saturation.
renal replacement therapy
The ICU team should be
(CRRT) may be considered.
warned to aspirate these be Novel dialysis systems with simple single-needle access
and automated citrate anticoagulation may enable the
CRRT machines that use
fore using the catheter during
safe use of sustained low-efficiency dialysis with arterioveprepackaged, sterile dialyresuscitation to avoid temponous fistula access in the future.
sate and/or replacement
rary ionized hypocalcemia in
fluids deliver 25-100 mL/
the right atrium and ventriminute diffusive and/or
cle. Finally, the appropriateconvective Kurea and operate at a QB of 100-300 mL/
ness of continued aggressive ICU support in light of the
minute and a dialysate and/or replacement fluid flow of
patient’s clinical course and previously stated advance di25-100 mL/min 24 hours a day. Sustained low-efficiency
rectives (if available) should be evaluated periodically todialysis (SLED) is a so-called hybrid therapy that is usually
gether with the ICU team and the patient or the
intermittent and uses an IHD machine to deliver 90-250
surrogate decision-maker.
mL/minute diffusive Kurea operating at a QB of 200-300
mL/minute and a QD of 100-300 mL/minute over a proRRT
longed period of 8-16 hours.12
Most ESRD patients rely on an AVF or AVG for HD acDialysis Modality Selection
cess. This is cannulated with an arterial needle to withdraw uremic blood and a venous needle to return
The proportion of ESRD patients maintained on PD may
dialyzed blood to the patient during IHD, and the operavary by country and region, resulting in varying utilizator stays at the bedside to continuously monitor the
tion of PD in the ICU. Continued use of PD in the ICU
may be difficult because of many factors, including the
patient. In the event of a return needle disconnect, lifelack of cycler equipment and/or continuous ambulatory
threatening blood loss could occur in 2-5 minutes. There
peritoneal dialysis (CAPD)-trained ICU nurses, particuis no commercial technology that would provide 100%
larly during nocturnal shifts. On the other hand, PD
protection against this complication, although some reuse in the ICU is prevalent and represents a successful,
cently approved monitoring systems may reduce the
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Table 1. Problem-Focused Evaluation of the ESRD Patient in the ICU
Critical illness
ESRD history

RRF protection
Dialysis access

Vein preservation
Volume status and UF

IVFs
Laboratory studies
Dialysis adequacy

Antibiotic dosing
Other medications

Cause of admission to the ICU with evaluation and management plan.
Cause and duration of ESRD; hepatitis B surface-antigen status; outpatient dialysis prescription including
outpatient urea kinetic volume of distribution (V), activated vitamin D and erythropoietin dose, code status,
end-of-life wishes, and advance directives for dialysis withdrawal in ICU.
Particularly important in PD patients. Limit IV radiocontrast dye and nephrotoxic medication (eg,
aminoglycoside) exposure as feasible.
Assess for signs of infection. Document the patency of AVF or AVG daily. Ensure proper care of the PD catheter
and exit site. Confirm that blood flow is sufficient to achieve the goals of therapy. ICU teams should avoid
placing a blood pressure cuff, arterial- or central venous lines, or doing venipuncture on the access arm.
Obtain blood samples with dialysis or from existing IV- or arterial lines to minimize venipuncture. Limit
placement of peripherally inserted CVCs and subclavian venous catheters as feasible.
Assess patient weight and fluid intake and output at least daily. Monitor absolute value and trend of central
venous pressure and central venous oxygen saturation (ScVO2) as well as invasive arterial blood pressure
and computerized pulse waveform analysis data when available.
Use isotonic IVFs when possible. Calculate the hyponatremic effects of the free water load from certain IV
antibiotics, vasopressors drips, and N-acetylcysteine infusions usually provided in 5% dextrose water.
Monitor at least daily chemistry profile, albumin, calcium, magnesium, phosphate, and complete blood count.
Monitor blood cultures and cardiac laboratory tests as indicated.
Measure the delivered dose of small-solute clearance (OLC) with every IHD session and deliver at least 1.2 Kt/V
(using outpatient or estimated V) 3 times per week. Provide extra treatments as needed for optimal volume
and solute control.
Dose antibiotics in close coordination with the pharmacist, considering drug levels, residual kidney function,
delivered small-solute clearance, and clearance of the drug with the modality of RRT and dialyzer utilized.
Verify and adjust as needed the dose of blood pressure drugs, digoxin, seizure, and other medications with
limited clearance in ESRD.

risk.13 As a result, double-needle access of AVF and AVG
cannot be recommended for safe use to provide either
SLED or traditional CRRTin which the ICU nurse operator
is not expected to stay at the bedside all of the time. In the
absence of a clear survival advantage of CRRT over IHD
(plus extrapolating from neutral studies in the acute kidney injury [AKI] population14) and considering the need
for temporary catheter access for the former, ESRD patients with working AVF and AVG usually receive IHD
in the ICU. ESRD patients with pre-existing HD catheter
access may conveniently receive any RRT modality. In patients with AVF or AVG who have indications for CRRT
(eg, severe hemodynamic instability on vasopressors,
marked fluid overload requiring high daily cumulative
fluid removal, or high risk of developing increased intracranial pressure [eg, with fulminant liver failure]) the possible complications of placing a temporary HD catheter to
allow CRRT use must be weighed against the risks of continued use of IHD with the AVF or AVG. In the near future,
machines with novel blood pumps15 may become available enabling safe, single-plastic-needle access of AVF or
AVG for 10- to 12-hour SLED. Compared with traditional
CRRT, SLED is associated with important cost savings16,17
and still allows for gentler solute and volume removal
than IHD. Taken together, these developments may
favor SLED over traditional CRRT and IHD use in ICU
ESRD patients in the future.

Assessment of the Adequacy of HD in the ICU
In the AKI ICU literature, several recent, large, randomized, and controlled studies have failed to confirm that

the delivered dose of small-solute clearance has an effect
on survival in a broad dosing range once a minimally
sufficient dose of uremic clearance is provided.18,19
Likewise, a large, randomized, and controlled study in
the stable outpatient HD population failed to show
that increasing the dose of small-solute clearance beyond current Kidney Disease Outcomes Quality Initiative guidelines would lead to better survival.20 Taken
together, these data make it implausible that a simple
escalation of delivered small-solute clearance beyond
outpatient targets would lead to better outcomes in the
critically ill ESRD patient. In the absence of strong
evidence-based guidelines for small-solute clearance
dosing targets in the ICU ESRD population, the authors
believe that the recently published Kidney Disease:
Improving Global Outcomes dosing guidelines for IHD
and CRRT for ICU AKI patients21 may also be applied
as reasonable and simple dosing goals for ESRD
patients.
However, different from the outpatient setting, ESRD
patients in the ICU often require accurate dosing of lifesaving medications (eg, antibiotics in sepsis), and measurement of the delivered solute clearance may become
more relevant to outcomes if it is applied to the complex
challenge of precisely dosing dialyzable drugs.22,23
Further, when a life-threatening electrolyte disorder (eg,severe hyperkalemia) or profound metabolic acidosis (eg,
toxic alcohol ingestion) is diagnosed, being immediately
able to measure the delivered small-solute clearance to
confirm the efficacy of the RRT procedure in real time
may be important and may allow for the detection of
a dysfunctional, recirculating access sooner than possible
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with the traditional method of analyzing serum chemistry trends on RRT.
Formal urea kinetic modeling, the gold standard of
measuring the delivered dose of small-solute clearance
during IHD in the outpatient setting, is difficult to perform in the ICU.24 Traditional anthropomorphic equations25 used to estimate the urea kinetic volume (V)
usually do not correlate well with the much larger true
V in the edematous, 10- to 20-L volume overloaded typical ICU patient. The urea generation rate may also be variable and usually increased in the critically ill catabolic
patient.26 Because ICU IHD and CRRT are not infrequently prescribed with no or reduced anticoagulation
when compared with outpatient IHD, a gradual decline
of the dialyzer performance during a single RRT session
is possible and may also contribute to a delivered clearance lower than prescribed. All of these factors can be accounted for, and simplified equations can be used,27
making urea kinetic modeling eventually feasible in expert academic settings.28 However, the precise sampling
and complex calculation requirements including possible
considerations of cardiac output (CO) and systemic vascular resistance (SVR) in the regional blood flow model
in critically ill patients may question the feasibility of
this approach in routine clinical practice.29
Fortuitously, the delivered small-solute clearance can
be measured automatically and without cost or risk to
the patient using the online clearance (OLC) measurement available on several modern IHD machines.11 The
measurement requires dialysate flow above 300 mL/minute for the rapid modulation of the fresh dialysate sodium (Na) level in the range of 135-155 mEq/L and
takes a few minutes to complete. The machine detects
the electrical conductivity changes of the fresh and spent
dialysate in response to the programmed changes in the
fresh dialysate Na level. The way the technology is implemented on the market leader commercial dialysis machine limits the net amount of Na transferred between
patient and dialysate to clinically negligible.30 The effective ionic dialysance (Kecn; about equal to effective Na
dialysance and effective urea clearance) is calculated in
milliliters per minute; a decline of the dialyzer performance due to partial clotting and access recirculation
(AR) reduce its value.30 The blood temperature monitor
(BTM; Fresenius) has multiple functions including measuring the temperature of the incoming and return limbs
of the blood circuit to detect AR. For AR measurements,
the IHD machine rapidly changes the temperature of the
fresh dialysate, thereby indirectly changing the temperature of the venous return blood, and then senses any corresponding temperature change in the incoming blood
that should only be observed if AR is present.31 Correlating the online, automatically determined Kt with the
apparent urea volume of distribution determined preferably with bioimpedance spectroscopy allows for the determination of the urea Kt/V with clinically sufficient
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accuracy and without the need for blood sampling and
complex calculations.32 OLC can also be obtained in
10-hour SLED using a commercial dialysis machine operating in IHD mode for 10 hours at a QB of 170 mL/
minute and a QD of 400 mL/minute as recently shown
by our group.33 This approach will lessen the uncertainty
about the delivered small-solute clearance during SLED,
which made antibiotic dosing difficult and a plausible
impediment to the wide adoption of the modality in the
past.34,35
Finally, optical detection of ultraviolet-light-absorbing
solutes in the waste dialysate with simple, low-cost technology was applied to indirectly monitor the delivered
urea Kt/V in real time during IHD, and the technology
is now available commercially.36 Distinct from ionic dialysance, optical effluent sensing allows for continuous dialysate solute-level monitoring with immediate detection
of changes. Application of this sensor to IHD and intermittent SLED in the ICU may be desirable, but it requires
validation. However, because the Kt/V calculations rely
on time-dependent reductions in effluent solute concentrations during intermittent therapy, the technology as
described would be inapplicable during 24-hour CRRT
with constant effluent solute levels in steady state.
In summary, ascertaining the delivered dose of smallsolute clearance is feasible now with commercially available OLC technology. Further research in the ICU ESRD
population is needed to confirm if OLC can be used to
guarantee the delivery of a minimum dose of dialysis
equivalent to the Kidney Disease Outcomes Quality
Initiative-recommended outpatient 3-times-per-week 1.2
Kt/V HD dose, to immediately detect ineffective dialysis
due to AR or partial dialyzer clotting, especially when
patients with emergent electrolyte and acid-base changes
are treated, and to precisely estimate the dialytic removal
of important medications, particularly of drugs for which
laboratory measurements are not readily available.
Once the delivered Kt/V is measured, the optimal
fresh dialysate Na, potassium (K), and bicarbonate concentration may be adjusted during the RRT session, taking into consideration the patient’s kinetic volume and
predialysis chemistry and the rate of development of
hyperkalemia and acidosis (or in rare clinical scenarios
alkalosis) to result in an optimal postdialysis serum electrolyte profile. Generally, postdialysis hypokalemia and
metabolic alkalosis should be avoided to lessen the risk
of cardiac arrhythmias; therefore, when a large Kt/V is
delivered (eg, with prolonged IHD or SLED), fresh dialysate Na, bicarbonate, and K levels should approximate
normal plasma chemistry values. It may also be prudent
to use a fresh dialysate Na level (possible range on the
market leader dialysis machine 130-155 mEq/L) within
10 mEq/L of the patient’s predialysis serum Na concentration to avoid an unduly large magnitude and rapid
rate of correction of preexisting hyponatremia or hypernatremia, which may also be predicted based on
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estimates of total body water and online-measured electrolytic conductivity clearance (Kecn).37 ESRD patients
with serum Na below 120 or above 165 meq/L are rarely
encountered; such patients initially may require CRRT
with custom-prepared replacement fluid Na levels to
avoid unduly rapid correction of their severe dysnatremias. A fair estimate of the bicarbonate delivery during
RRT may also be calculated from the delivered ionic dialysance and the average bicarbonate gradient between the
patient’s systemic plasma and the fresh dialysate. This information may be important to the ICU team to clearly
define the severity of ongoing metabolic acidosis, which
may be completely masked by several hundred millimoles of bicarbonate provided by the RRT session. The
most common example is the development of lactic acidosis during SLED; this sometimes may go unnoticed unless the anion gap is corrected for hypoalbuminemia and
trended and/or a dedicated lactate measurement is ordered.

Hemodynamic Optimization including Fluid
Therapy and UF
Fluid Administration to ESRD Patients
ESRD patients admitted to the ICU may have low effective arterial blood volume and hemodynamic instability
due to any combination of cardiac dysfunction, sepsis,
severe liver disease, gastrointestinal bleeding, volume
depletion, and third spacing after extensive surgery
with or without overall extracellular fluid (ECF) volume
reduction. Restoration of intravascular volume and circulation may require the administration of large volumes of
intravenous fluids (IVFs). In the absence of ESRD patientspecific guidelines, the authors believe it is reasonable to
assume that the principles of early goal-directed therapy38 may also be applicable to the ESRD population
with the obvious caveat that excess fluid infusion is
more difficult to correct in anuric patients. However, by
definition, anuric ESRD patients are unable to regulate
their ECF tonicity without urine output, and even patients who have RRF are unlikely to be able to generate
a significant medullary osmotic gradient and thereby variable urine tonicity. Therefore, to maintain a normal serum Na concentration and tonicity, the use of isotonic
IVFs is usually required. In these patients, the effect on
an ECF Na concentration of 1 L of IVF gained or 1 L of
body fluid lost with a specific Na and K content can be
reliably calculated and predicted.39,40 The hyponatremic
effect of hypotonic infusions (eg, vasopressors, Nacetylcysteine) and certain antibiotics administered in
5% dextrose-water IVF commonly used in the ICU
should be predicted and if needed mitigated with the
use of a higher Na fresh dialysate. When such calculations are omitted (eg, when a small ESRD patient receives
5-6 L of 0.45% half-isotonic saline perioperatively), clini-

cally dangerous hyponatremia will develop, inexorably
necessitating emergent dialytic correction. Even when
ECF expansion is achieved while maintaining normotonicity, it is very difficult clinically to avoid ‘‘overshoot’’
and the development of varying degrees of ECF overload
with or without pulmonary congestion in this usually anuric population. Finally, even if meticulous attention is
paid to hemodynamic monitoring during IVF administration, pulmonary edema may develop with the resolution of the initial systemic inflammatory response
syndrome (SIRS) causing rapid mobilization of thirdspaced ECF volume, again requiring extra session(s) of
or CRRT.

Hemodynamic Assessment to Guide UF Goals
Fluid overload may be present on ICU admission or may
complicate the fluid therapy of critical illness in ESRD patients, and fluid overload is known to be associated with
poor clinical outcomes in AKI.41 A major goal of kidney
support is to reduce the extracellular volume expansion
with UF. However, it is very difficult to do this safely
without compromising organ perfusion because patients
are often hemodynamically unstable with insufficient intravascular refill rates that can fluctuate dramatically.42
To guide IVF use, ICU teams often place catheters in
the internal jugular vein with ultrasound guidance to
monitor the absolute value and the trend of the superior
vena cava O2 saturation (ScVO2) and central venous pressure in preference to the prior practice of using pulmonary artery catheters. The ScVO2 is generally accepted
as a useful, dynamic, surrogate marker of CO at unchanged arterial O2 content and body O2 consumption,
with a lower value signifying a lower CO state.43 ScVO2
has also been associated with outcomes and complications after major surgery,44 and optimization of ScVO2
is a component of early goal-directed therapy for
SIRS.38 Computerized arterial pressure waveform analysis on dedicated devices may complement such monitoring because an arterial pressure line is usually in place in
these patients. Obtaining a two-dimensional echocardiogram to define right and left ventricular systolic function,
to detect and grade valvular heart disease, and to assess
the presence of a pericardial effusion is noninvasive and
may prove very helpful.

UF with Online Monitoring
Rapid net UF during IHD can lead to variable degrees of
hemoconcentration and a corresponding relative reduction in the circulating blood volume with the ultimate development of hypotension and organ hypoperfusion. It is
possible to detect this phenomenon in real time by integrating a low-cost, disposable optical chamber into the
dialysis blood circuit prefilter and using a commercial
optical hematocrit, relative blood volume, and O2 saturation monitor. A pulse oxymeter-like sensor clips onto the
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chamber from the outside and measures blood absorption of transmitted light at multiple wavelengths. The
device calculates and displays the hematocrit, the hemoglobin level, and the O2 saturation of the circuit incoming
blood in real time. When the dialysis catheter tip is in the
superior vena cava, the monitor essentially displays the
ScVO2 online at a negligible cost compared with a dedicated ScVO2 monitoring catheter and device, and it
may help to reduce net UF rates that are not tolerated before dangerous hemodynamic compromise develops.
Conversely, blood volume monitoring was not useful to
predict hypotension in the ICU,45 but it could help detect
catastrophic overultrafiltration, which rarely can and
does happen due to operator error or equipment malfunction.46 It is important to note that reliable readings
during IHD and SLED may require very effective
anticoagulation to prevent biofouling of the optical chamber. Once it develops, intradialytic hypotension may be
treated by reducing the hourly net fluid removal rate
and by small IVF or albumin boluses. The use of a slightly
colder fresh dialysate temperature of approximately 35.035.5 C during IHD may also help lessen the incidence of
hypotension by providing a mechanism to maintain the
core temperature of the patient without the need for
skin vasodilatation and increased perfusion for heat
loss through radiation to the environment. Conversely,
heat loss from the blood circuit during SLED and CRRT
is essentially guaranteed because of the lower blood
and dialysate or replacement fluid flows. Therefore, the
use of a dialysate temperature below 36.5 C (including
CRRT without a fluid warmer) is not recommended because it may lead to clinically significant hypothermia
and mask a febrile state.

ticoagulants have been used during ICU dialysis and
were recently reviewed.49 However, all of these drugs, including heparin, have significant side effects and most
importantly can increase the risk of systemic bleeding.
Regional citrate anticoagulation (RCA) is a very effective method to prevent clotting of the extracorporeal
blood circuit without any systemic bleeding tendency.
The procedure has gradually gained ground for CRRT
and has been applied during IHD and 8- to 10-hour
SLED.17,50 RCA is now recommended in the Kidney
Disease: Improving Global Outcomes Clinical Practice
Guideline for Acute Kidney Injury as the method of
choice for anticoagulation of CRRT circuits when citrate
use is not contraindicated.21 However, RCA use in nonexpert centers has been limited by concerns about severe
electrolyte complications including hypercalcemia or
hypocalcemia, hypernatremia, metabolic alkalosis, or
acidosis, particularly in patients with shock and severe
liver dysfunction. These complications were noted less
frequently when RCA was used during intermittent
SLED17,50 and the principles of safe, near-automated delivery of RCA for IHD and SLED were described.51
In our large ICU RRT program serving 160 ICU beds in
a single center, we have been using 10- and 24-hour
SLED-RCA protocols safely for many ESRD patients
with catheter access even in the presence of severe liver
dysfunction and/or shock.33 Citrate accumulation and
electrolyte abnormalities due to RCA are not observed,
and clotting of the extracorporeal circuit is virtually never
seen. In the future, 10-hour SLED-RCA may also increase
the use of single-needle access of AVF and AVG in the
ICU by eliminating the clotting risk inherent to the intermittent circuit blood flow.52

Anticoagulation During IHD, SLED, or CRRT

Quality Improvement Initiatives

ESRD patients are at increased risk of bleeding in the ICU
because of uremic platelet dysfunction and the possible
presence of recent surgical wounds or gastrointestinal arteriovenous malformations. For brief (3- to 5-hour) IHD
anticoagulation-free treatment sessions, saline flushes of
the blood circuit may suffice. Use of acid concentrates
with a final 1X dialysate content of 2.4-3 mEq/L citric
acid as opposed to 3-4 mEq/L acetic acid may also
have a modest anticoagulant effect. However, when using citric-acid-based dialysate, a 0.5-mEq/L higher dialysate calcium content may be necessary to achieve the
same systemic ionized calcium level as with a 3- to 4mEq/L acetic-acid-based dialysate.47 Less thrombogenic
blood circuits, catheters, and dialyzers incorporating
novel surface-modifying macromolecules48 and airless,
nonturbulent blood flow pathways are in development
and may be helpful in the future.
When an anticoagulant is necessary, the use of unfractionated heparin may be attempted because it is relatively
short-acting and its effect can be reversed. Many other an-

ICU Dialysis Telemetry
In outpatient HD, telemetry collection of dialysis machine data during treatment is becoming mandatory in
the United States. For example, one of the largest outpatient dialysis providers has been collecting online smallsolute clearance data from its units as a proposed
adequacy assessment and targeting tool for about a decade.53,54 Computer and software technology developed
for this purpose are easily adaptable to monitor IHD
and SLED treatments provided in the ICU to ESRD
patients.33 Such data collection could confirm the duration of RRT, the delivered small-solute clearance, and
the frequency and cause of machine alarms leading to
treatment interruptions. This would be of obvious interest in the ICU, where considerably more variation in
patient condition, treatment prescriptions, and complications occurs than in the outpatient setting. The wirelessly
collected data can be stored on secure servers and used in
real-time and post hoc quality monitoring and quality
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improvement projects; we are now implementing such
a program.33

Communication Between Providers
The importance of daily, detailed communication between
the ICU team and the pharmacist was discussed earlier. A
detailed report to the outpatient nephrologist about the
hospital course and postdischarge care plan is also indispensable. ESRD patients may experience marked weight
loss after a protracted ICU stay, which must be communicated for an immediate lowering of the estimated dry
weight used in the outpatient dialysis center to correctly
set net UF goals and prevent volume overload due to the
use of an outdated, higher estimated dry weight. Conversely, patients may be discharged still recovering from
SIRS with reduced blood pressure medications and significant ECF overload from earlier IVF therapy. Such patients
may need daily outpatient HD for a few days for volume
control and a gradual increase in blood pressure medications as they recover fully. Antibiotic therapy started in
the ICU is often completed with postdialytic dosing in
the outpatient HD unit. Detailed communication of the indication, duration, and dose of each agent is indispensable
for optimal care. Changes to the outpatient medication
regimen (eg, antihypertensive pills after an admission
for uncontrolled hypertension) must also be communicated to allow the HD unit to monitor the effects of and
compliance with the new drug schedule.

Discharge Planning to Prevent Re-Admissions
ESRD patients have an increased risk of mortality after
the survival of an ICU admission, and in the United
States the 30-day hospital re-admission rate of ESRD patients is very high at 36%.1,55 Communicating in simple
terms to the patient and family the cause of the hospital
admission and the main treatment received is
important for compliance with the care plan after
discharge. In particular, compliance with the outpatient
dialysis, diet, and adjusted medication regimen must be
emphasized. Access to follow-up with the primary doctor and adequate insurance coverage and financial means
to obtain the prescribed medications should be ascertained. Postdischarge follow-up phone calls and a home
visit by a nurse can also help monitor and ensure patient
compliance with the discharge plan.

Summary
ESRD patients are frequently admitted to the ICU, and
their management poses many unique challenges. Meticulous attention to IVF therapy, optimization of hemodynamic status, medication dosing, and sophisticated use
of multiple RRT strategies are all important elements of
critical care support. Recognizing the higher risk of subsequent morbidity and mortality in ESRD patient ICU

survivors and developing a comprehensive, multidisciplinary team strategy during the ICU stay and the discharge process may help improve outcomes and reduce
hospital re-admissions.
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